Pharma Companies Agree to Medicare Drug Price Negotiations
Pharmaceutical companies have agreed to negotiate prices for 10 drugs.
RSS News Feed
Latest
Biomarker-Guided First-Line Treatment Improves OS in Advanced NSCLC
First-line treatment guided by biomarker testing results improves survival in patients with advanced non-small cell lung cancer, a study suggests.
Best Outcomes With First-Line Treatment for Unresectable ESCC
Researchers have identified first-line treatment regimens that appear to be associated with the best outcomes in advanced, unresectable ESCC.
Use of Palliative Care in Metastatic Breast Cancer Varies by Race/Ethnicity
New research suggests that, in the United States, the use of palliative care for metastatic breast cancer varies by race.
Many Oncology Practices Do Not Screen for Caregiver Well-Being
Caregivers of adult cancer patients are not typically screened for distress, a new study suggests.
Odronextamab Granted Priority Review for Rel/Ref FL, DLBCL
The FDA has accepted for priority review the biologics license application for odronextamab to treat adults with relapsed/refractory FL or DLBCL whose disease has progressed after at least 2 prior systemic therapies.
Nobel Prize Awarded to mRNA Pioneers
This year’s Nobel Prize in physiology or medicine has been awarded to 2 scientists who laid the groundwork for the mRNA research that made COVID-19 vaccines possible.
Breast Cancer Symptoms By Stage (1-4)
Breast Cancer Awareness Month promotes education on testing and detecting breast cancer early. This means understanding breast cancer symptoms, and how the disease progresses by stage. Does the staging of breast cancer affect symptoms?
Discrimination Motivates Clinical Trial Participation, Survey Suggests
Patients who experience high levels of discrimination are more willing to participate in clinical trials, a survey suggests.
Excellent Adherence to Hormone Therapy Deemed “Critical” for DCIS Patients
Excellent adherence to hormone therapy after surgery for DCIS can improve outcomes, when compared to good or low adherence, researchers say.
Prophylactic Radiation Improves Outcomes in Patients With Metastatic Solid Tumors
Prophylactic radiation for asymptomatic bone metastases can improve outcomes in patients with solid tumor malignancies, a phase 2 study suggests.
Dendritic Cell Vaccine May Improve ASCT Outcomes in Multiple Myeloma
A dendritic cell vaccine, when given before and after stem cell transplant, may improve responses in patients with multiple myeloma, researchers say.
FDA Intends to Increase Oversight of Laboratory-Developed Tests
The FDA has become “increasingly concerned” that some laboratory-developed tests may not provide accurate results.
Insurance Issues With COVID-19 Vaccines Mostly Fixed
Some people have been denied insurance coverage while seeking COVID-19 vaccinations at pharmacies.
AI in Oncology: Current and Future Applications
AI has been used in oncology for years, but recent studies suggest AI could have many additional applications in cancer care.
Adverse Events Associated With Antibody-Drug Conjugates Across Cancer Types
Researchers say they have identified adverse events that are more likely to occur in cancer patients receiving antibody-drug conjugates.
Local Therapy Improves Overall Survival in cN1 Prostate Cancer
Local therapy improves overall survival in patients with clinically lymph node-positive prostate cancer, a meta-analysis suggests.
Decrease in New Cancer Diagnoses Seen in 2020
There was a decrease in new cancer diagnoses, relative to expected numbers, between March 2020 and May 2020, according to a report.
Bariatric Surgery Linked to Lower Risk of Hematologic Cancer
Bariatric surgery is associated with a lower risk of hematologic cancer in women, a study suggests.
Diabetes Increases Risk of Upstaging in RCC
Diabetes increases the likelihood of upstaging in patients with clinical T1 RCC undergoing partial or radical nephrectomy, a study suggests.
Study Evaluating Magrolimab in Patients With TP53-Mutant AML Discontinued
Gilead has discontinued the ENHANCE-2 study, which was designed to evaluate magrolimab in AML patients with TP53 mutations.
What Happens to Health Programs if the Federal Government Shuts Down?
For the first time since 2019, congressional gridlock is poised to temporarily shut down big parts of the federal government, including many health programs.
Survey: Most Cancer Patients Use Complementary or Alternative Medicine
In a recent survey, 70% of cancer patients said they use complementary or alternative medicine as part of their cancer care.
Studies Reveal Rhabdomyosarcoma Patients Who Benefit From Radiotherapy
Researchers say they have identified which patients with rhabdomyosarcoma are most likely to benefit from radiotherapy.
Successes and setbacks in prostate cancer care
Seeking the right treatment for the right patient at the right time By PRI Healthcare Solutions At the beginning of 2023, the American Cancer Society annual report on prostate cancer took a page from A Tale of Two Cities: It was the best of times, it was the worst of times … it was the…
Good Oral Health Linked to Improved Survival in Head and Neck Cancer
Good oral health is associated with improved survival in patients with head and neck cancer, a study suggests.
Bosulif Approved for Pediatric Patients With Chronic Phase Ph+ CML
The FDA has approved bosulif (bosutinib) for patients aged 1 year or older with chronic phase Ph+ CML.
US Adults May Be Hesitant to Receive Updated COVID-19 Vaccines
More than half of US adults surveyed said they “definitely” or “probably” won’t be vaccinated with one of the updated COVID-19 vaccines.
Clinical Trial: Atezolizumab Plus Trastuzumab Emtansine in HER2+ Breast Cancer
Researchers are evaluating the effects of adding atezolizumab to adjuvant treatment with trastuzumab emtansine in patients with HER2-positive breast cancer.
US Military Service May Impact Risk of Certain Cancers
Researchers have found several differences in cancer rates between members of the US military and the general US population.
Genes Linked to Aggressive Prostate Cancer
Researchers say they have identified genes that should be considered for gene panel testing in prostate cancer.
Alpelisib-Associated Hyperglycemia May Be More Common in Practice Than in Trials
Patients with metastatic breast cancer who receive alpelisib in clinical practice have higher rates of hyperglycemia than patients who receive the drug in clinical trials, a new study suggests.
Adding Novel Agents to Durvalumab Improves Responses in NSCLC
Combining neoadjuvant durvalumab with other agents improves response rates in patients with resectable non-small cell lung cancer.
Increased Exposure to PFAS, Phenols, and Parabens Linked to Prior Cancer Diagnosis
Higher exposure to PFAS, phenols, and parabens is associated with previous cancer diagnosis in women but not men, a study suggests.
Pfizer Restarts Production Plant in North Carolina Following Tornado Damage in July
A Pfizer plant that makes drugs and hospital supplies has restarted production after a 10-week shutdown.
Clinical Trial: Dato-DXd With or Without Durvalumab in Stage I-III TNBC
Researchers are conducting a phase 3 trial to compare Dato-DXd, with or without durvalumab, to investigator’s choice of treatment in patients with TNBC.
State Policies May Prevent Cancer Patients From Using Telehealth
Privately-insured cancer patients living in states with restrictive telehealth policies were less likely to use telehealth in 2020 and 2021, a study showed.
Surgery Does Not Improve OS in Patients With De Novo Metastatic Breast Cancer
Surgery to remove the primary tumor does not prolong overall survival in most patients with de novo metastatic breast cancer, a meta-analysis suggests.
High-Dose Chemo and HSCT Linked to Second Primary Malignancies in Lymphoma Survivors
Lymphoma patients who receive high-dose chemotherapy and autologous HSCT have an increased risk of second primary malignancies, data suggest.
Less Aggressive Chemoradiation for MIBC Tested in Noncystectomy Patients
Investigators tested a less aggressive chemoradiation protocol in patients with MIBC who were unfit for surgery due to age or comorbidities.
Comparing Medicare Drug Plans May Ease Financial Toxicity for Prostate Cancer Patients
Comparing Medicare Part D plans can reduce financial toxicity associated with the use of oral androgen inhibitors in patients with advanced prostate cancer, a study suggests.
Nighttime Aromatherapy Improves Well-Being in Hospitalized Patients With Cancer
The use of aromatherapy at night improved mean scores of well-being in patients with cancer in a hospital setting.
Certain Breast Cancer Patients Can Safely Forgo Axillary Surgery
Breast cancer patients without axillary lymph node involvement who have tumors no larger than 2 cm can safely forgo axillary surgery, a phase 3 trial suggests.
HIPEC Improves Long-Term Outcomes in Stage III Ovarian Cancer
Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.
NGS-Guided Treatment Is Feasible for Platinum-Refractory Head and Neck Cancer
Using next-generation sequencing to guide treatment is feasible in patients with platinum-refractory head and neck cancer, according to researchers.
Breast Cancer Risk Higher for Childhood Cancer Survivors Who Received Doxorubicin
Female survivors of childhood cancer have a higher risk of subsequent breast cancer if they received doxorubicin, a study suggests.
Prostate Cancer Biochemical Recurrence Risk Stratification Falls Short
As currently defined, biochemical recurrence after surgery or radiation is not a reliable predictor of the risk of death from prostate cancer, investigators say.
CMS: Medicaid Reinstated for Nearly 500,000 Children and Families
About 500,000 children and families have had their Medicaid reinstated after losing it because of a systems issue.
New YouTube Policy Targets Cancer Misinformation
Online misinformation is harming cancer patients. YouTube has been part of the problem, but a new policy might change that.
Dabrafenib Plus Trametinib Bests Chemo in Kids With BRAF-Mutant Glioma
First-line treatment with dabrafenib and trametinib can improve outcomes, when compared to standard chemotherapy, in children with BRAFV600-mutated low-grade glioma, a phase 2 trial suggests.
OSE2101 Vaccine Outperforms Standard Care in Certain Patients With NSCLC
The cancer vaccine OSE2101 improved survival in patients with HLA-A2+, advanced NSCLC and secondary resistance to ICIs in a phase 3 trial.
Radiotherapy for Prostate Cancer Linked to Higher Risk of Bladder and Lung Cancer
Prostate cancer patients treated with radiotherapy have a higher risk of developing and dying from bladder cancer or lung cancer than patients treated with radical prostatectomy alone, a study suggests.
Risk of Albuminuria Higher With Dasatinib Than With Other TKIs
Patients with CML have a higher risk of albuminuria if they receive dasatinib rather than other TKIs, a study suggests.
FDA Fast Tracks TMPRSS6 Inhibitor for Polycythemia Vera
The FDA has granted fast track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.
US Resumes Free COVID-19 Test Program
The government will pay for about 200 million at-home COVID-19 tests to replenish the country’s stockpile.
Cisplatin Shortage Nearly Resolved; Supplies of Carboplatin, Methotrexate Increasing
The US supply of cisplatin is nearly restored, and shortages of carboplatin and methotrexate have been alleviated, the government says.
Ranitidine Does Not Increase the Risk of Cancer, Study Suggests
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
Breast Cancer Detected in Breast Milk Earlier Than in Plasma
Researchers say they have detected breast cancer in ctDNA from breast milk, and breast milk may allow for earlier cancer detection than plasma.
Testicular Cancer Guidelines Updated
Surveillance plays a major role in the management of men with cancer clinically confined to the testis.
Prostate Cancer Outcomes Worse With Higher Periprostatic vs Serum Testosterone
Local testosterone delivery to the prostate bed might be a better marker of post-prostatectomy outcomes than serum testosterone in some men.
Pembrolizumab Plus Chemoradiotherapy Under Review for High-Risk, Locally Advanced Cervical Cancer
Pembrolizumab plus chemoradiotherapy is under priority review for newly diagnosed, high-risk, locally advanced cervical cancer.
Oncologists Receive More EHR Messages Than Other HCPs but Spend Less Time in EHRs
A new study suggests that electronic health records could be better tailored to meet the specific needs of oncologists.
Global Burden of Lip and Oral Cavity Cancers, Other Pharyngeal Cancers
Researchers say they have quantified the global burden of lip and oral cavity cancers as well as other pharyngeal cancers.
Identifying Prognostic Factors in Pleural Mesothelioma
Researchers have validated previously identified prognostic factors for pleural mesothelioma and identified “room for improvement” when predicting overall survival in this patient population.
Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Ojjaara Approved for Intermediate or High-Risk Myelofibrosis With Anemia
The FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.
Belzutifan Gets Priority Review for Advanced Renal Cell Carcinoma
The FDA has accepted for priority review the supplemental new drug application for belzutifan to treat adults with advanced renal cell carcinoma who previously received immune checkpoint and anti-angiogenic therapies.
Mississippi’s Cervical Cancer Deaths Indicate Broader Health Care Problems
Mississippi had the nation’s second-highest age-adjusted cervical cancer mortality rate from 2016 through 2020.
Air Pollution Linked to Increased Risk of Breast Cancer
Long-term historical exposure to air pollution is associated with an increased risk of breast cancer, a new study suggests.
Cardiovascular Events After ICI Therapy “Common” in Lung Cancer
Cardiovascular toxicity related to immune checkpoint inhibitor therapy is “common” in patients with lung cancer, a new study suggests.
Patients With HER2+ Metastatic CRC Aren’t Receiving Guideline-Concordant Care
Data suggest that many patients with HER2+, metastatic colorectal cancer do not receive HER2-targeted therapy as recommended by NCCN guidelines.
Dose-Intensive Chemoimmunotherapy “Preferred” for Untreated PMBCL
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
In Situ and Invasive Melanoma Diagnoses Decreased From 2019 to 2020
Diagnoses of in situ and invasive melanoma were stable from 2018 to 2019 but decreased from 2019 to 2020, researchers found.
Cancer Deaths Increased During the First 2 Years of the COVID-19 Pandemic
Cancer deaths increased during the first 2 years of the COVID-19 pandemic in the United States, a population-based study suggests.
7-8 Years of Adjuvant Endocrine Therapy Deemed Sufficient in Postmenopausal Breast Cancer
Taking adjuvant endocrine therapy for 7 to 8 years is likely sufficient for maximal disease-free survival benefits among most postmenopausal women with HR+ breast cancer, according to researchers.
COVID-19 Vaccines Increase PD-L1 Levels, Might Reverse Treatment Resistance in NSCLC
New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.
Atezolizumab Does Not Improve PFS in Recurrent, Platinum-Sensitive Ovarian Cancer
Adding atezolizumab to bevacizumab and platinum-based chemotherapy did not improve PFS in recurrent, platinum-sensitive ovarian cancer.
Adding Nivolumab to SABR Improves EFS in NSCLC
Adding nivolumab to treatment with SABR improved the 4-year event-free survival rate in a phase 2 trial of patients with NSCLC.
Temozolomide Prescribing Information Updated Under FDA’s Project Renewal Program
Temozolomide is the second drug to receive a labeling update under Project Renewal.
Breast Cancer Awareness Month: The History and Impact
When did Breast Cancer Awareness Month first begin, and what impact has it had on awareness and research in the years since?
Breakthroughs in Targeted Therapy, Immunotherapy Reduce Cancer Deaths
Breakthroughs in targeted therapy and immunotherapy are partly responsible for the recent decline in US cancer deaths, according to the AACR Cancer Progress Report 2023.
Can a Breath Test Detect Mesothelioma? It’s Too Soon to Tell.
Researchers are evaluating whether a breath test can detect malignant pleural mesothelioma in patients with asbestos exposure, and early results suggest it may be possible.
Eliminating H2RAs From Paclitaxel Premedication Does Not Increase Infusion Reactions
The use of H2RAs to prevent infusion-related reactions to paclitaxel should be reevaluated, according to researchers.
Tepotinib Plus Osimertinib May Provide Chemo-Free Option for NSCLC After First-Line Osimertinib
Tepotinib plus osimertinib has demonstrated efficacy in advanced, EGFR-mutant, MET-amplified NSCLC that progressed on first-line osimertinib.
Lowering Costs Can Improve Adherence to Adjuvant Endocrine Therapy
Lowering medication costs can improve adherence to adjuvant endocrine therapy in breast cancer survivors, an analysis suggests.
Opioids Can Be Continued in Cancer Patients Using Nonmedical Stimulants
Experts have recommended that, for patients with cancer-related pain who are using nonmedical stimulants, opioids should be continued, monitoring should be increased, and tapering should be avoided.
Vitamin C, D Supplementation During Chemo May Reduce Complications in AML
Taking vitamin C and D during chemotherapy may improve some outcomes for patients with AML, a new study suggests.
Lung Cancer Patients Have High Burden of COVID-19 Death in Omicron Era
US patients with lung cancer have a higher burden of death from COVID-19 than the general population, and this has been the case since the omicron variant became dominant, data suggest.
Atezolizumab Yields Durable Responses in Alveolar Soft Part Sarcoma
Atezolizumab produced sustained responses in more than a third of patients with alveolar soft part sarcoma in a phase 2 trial.
Intervention Enables Same-Day Genetic Testing for Ovarian Cancer Patients
A genetic testing station can increase uptake and improve the efficiency of genetic testing for patients with ovarian cancer, a study suggests.
Perioperative Durvalumab Does Not Impact Surgical Outcomes in NSCLC
Perioperative durvalumab does not adversely impact surgical outcomes in patients with resectable non-small cell lung cancer, results from the AEGEAN trial suggest.
Nimotuzumab Improves OS, PFS in KRAS Wild-Type Advanced Pancreatic Cancer
Adding nimotuzumab to treatment with gemcitabine improves survival outcomes in patients with KRAS wild-type advanced pancreatic cancer, a phase 3 trial suggests.
CDC Recommends Updated COVID-19 Vaccines for Everyone 6 Months and Older
The CDC is recommending wide use of the updated mRNA COVID-19 vaccines from Pfizer-BioNTech and Moderna.
Adding Serplulimab to Chemotherapy Improves Survival in Squamous NSCLC
First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.
First-Line Benmelstobart Regimen Produces Longest PFS, OS to Date in ES-SCLC
Adding benmelstobart and anlotinib to first-line chemotherapy improved survival outcomes in a phase 3 trial of patients with ES-SCLC.
Adagrasib Shows “Durable Clinical Benefit” in Advanced KRAS-Mutant NSCLC
Adagrasib has shown durable clinical activity in patients with advanced KRASG12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.
Patritumab Deruxtecan Deemed Effective in Resistant, EGFR-Mutant NSCLC
Patritumab deruxtecan (HER3-DXd) is effective in patients with previously treated, EGFR-mutant NSCLC, a phase 2 study suggests.
MARS 2: Chemo Alone May Be Superior to Surgery Plus Chemo in Mesothelioma
Chemotherapy alone may produce better outcomes than surgery plus chemotherapy in patients with mesothelioma, the MARS 2 trial suggests.
Adding Chemotherapy to Osimertinib Improves PFS in EGFR-Mutant, Advanced NSCLC
Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for patients with EGFR-mutant, advanced NSCLC, phase 3 data suggest.
Incidence of Lung Cancer Subtypes Varies by Region
Incidence rates of lung cancer subtypes vary across global regions, data suggest.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...